Joshua Russo
@jrpcfer.bsky.social
Prostate cancer researcher at Beth Israel Deaconess Medical Center/Instructor at Harvard Medical School.
Reposted by Joshua Russo
Where does TrumpElon think innovation for all their favorite biotech corporations comes from? PCR only exists because somebody was looking for bacteria in hot springs at Yellowstone. I’m just a private practice ophthalmologist who barely understands p values but even I know this shit is important.
This is my institution. These are the people I work with making these decisions. The situation is heartbreaking. Public medical schools have no other choice; there is no other source of funding, and everyone in academia is at extreme risk right now.
March 13, 2025 at 2:12 PM
Where does TrumpElon think innovation for all their favorite biotech corporations comes from? PCR only exists because somebody was looking for bacteria in hot springs at Yellowstone. I’m just a private practice ophthalmologist who barely understands p values but even I know this shit is important.
Reposted by Joshua Russo
Maybe the crisis in seabirds with multi-organ failure from exposure to plastics will help raise awareness of their serious hazard and lead to action
science.org/doi/10.1126/...
science.org/doi/10.1126/...
March 12, 2025 at 8:52 PM
Maybe the crisis in seabirds with multi-organ failure from exposure to plastics will help raise awareness of their serious hazard and lead to action
science.org/doi/10.1126/...
science.org/doi/10.1126/...
Reposted by Joshua Russo
About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social
February 23, 2025 at 7:12 PM
About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social
Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility.
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer - PubMed
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We generated...
pubmed.ncbi.nlm.nih.gov
January 19, 2025 at 1:56 PM
Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility.
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/